HFA Congress 2026 — Dr Guillaume Baudry (University Hospital of Brabois, Nancy, FR) joins us to discuss findings from the UF-CARE trial, evaluating ultrafiltration against enhanced medical therapy in patients with type 2 cardiorenal syndrome.

This randomised, open-label study enrolled patients with severe, refractory heart failure and concurrent chronic kidney disease, a population with a high burden of repeated hospitalisation and markedly impaired quality of life despite optimal medical management. Patients were randomised to an ultrafiltration strategy (peritoneal dialysis, haemodialysis, or isolated ultrafiltration) or to intensive cardiology and nephrology follow-up with optimised medical care. The primary endpoint assessed all-cause mortality and unscheduled hospitalisation for acute decompensated heart failure at 12 months.

Interview Questions:

1. What is the clinical challenge posed by type 2 cardiorenal syndrome, and why has robust evidence for ultrafiltration been lacking until now?
2. How was the UF-CARE trial designed, and what patient population did it enrol?
3. What were the key findings?
4. Were there any meaningful differences in outcomes across the three ultrafiltration modalities?
5. How did quality of life and functional outcomes compare between the two arms?
6. What are the safety considerations for clinicians considering ultrafiltration in this patient group?
7. How should these findings inform the management of refractory heart failure with cardiorenal syndrome in routine practice?
8. What are the next steps for this research?

Recorded on-site at HFA Congress 2026, Barcelona.
Editors: Jordan Rance
Videographer: Oliver Miles, David Ben-Harosh
Support: This is an independent interview produced by Radcliffe Cardiology.